Comparison of targeting two antigens (GPA33 versus HER2) for ²²⁵Ac-pretargeted alpha-radioimmunotherapy of colorectal cancer.

ABSTRACT: Purpose: Curative therapies remain a significant unmet need for advanced human colorectal cancer (CRC). The aim of this study was to establish a 3-step ²²⁵Ac-DOTA pretargeted radioimmunotherapy (PRIT) system for human CRC, targeting two individual antigens: glycoprotein A33 (GPA33) and human epidermal growth factor receptor 2 (HER2). Methods: In vitro cellular uptake and internalization assays, as well as survival assays (colony forming) were performed in GPA33- and HER2-positive SW1222 human CRC cells. In vivo biodistribution and therapy studies were performed with two human CRC xenograft mouse models. Results: For both antigens, treatment with up to 74 kBq ²²⁵Ac-DOTA-PRIT in SW1222-tumored mice significantly enhanced overall surviv

SUBMITTER: Rinne SS 

PROVIDER: S-EPMC12315807 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature